(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 506.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.15%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.77%.
Argenx Se's revenue in 2023 is $10,665,957.On average, 10 Wall Street analysts forecast ARGX's revenue for 2023 to be $41,118,903,617, with the lowest ARGX revenue forecast at $30,433,596,953, and the highest ARGX revenue forecast at $59,176,069,213. On average, 8 Wall Street analysts forecast ARGX's revenue for 2024 to be $77,528,273,139, with the lowest ARGX revenue forecast at $64,868,547,376, and the highest ARGX revenue forecast at $90,203,842,118.
In 2025, ARGX is forecast to generate $137,119,035,731 in revenue, with the lowest revenue forecast at $109,905,378,304 and the highest revenue forecast at $172,774,135,278.